Recall of substandard medicines in Brazil during the period 2010-2018.

BMC Health Serv Res

Pharmacy Department, Faculty of Pharmacy, Dentistry and Nursing, Federal University of Ceará, Rua Pastor Samuel Munguba, 1210, Rodolfo Teófilo, Fortaleza, 60430-372, Ceará, Brazil.

Published: March 2023

Background: Even with all the care taken during the production process, the pharmaceutical industries are still subject to manufacturing medicines with quality deviations, generating commercialized products without the required quality and necessitating their subsequent recall from the market. The objective of this study was to evaluate the reasons that led to the recall of medicines in Brazil in the period evaluated.

Methods: This is a descriptive study (using document analysis), on the recall of substandard medicines registered on the website of the National Health Surveillance Agency (ANVISA), from 2010 to 2018. The variables studied were the type of medicine (reference, generic, similar, specific, biological, herbal, simplified notification, new and radiopharmaceutical), type of pharmaceutical dosage form (solid, liquid, semi-solid and parenteral preparation), and reason for recall (Good manufacturing practices, quality and quality/good manufacturing practices).

Results: A total of n = 3,056 recalls of substandard medicine were recorded. Similar medicines had a higher recall index (30.1%), followed by generics (21.3%), simplified notification (20.7%) and reference (12.2%). Different dosage forms had similar recalls: solids (35.2%), liquids (31.2%) and parenteral preparations (30.0%), with the exception of semi-solids (3.4%). The reasons for the highest occurrences were related to good manufacturing practices (58.4%) and quality (40.4%).

Conclusion: The probable cause for this high number of recalls is the fact that, even with all the quality controls and processes in accordance with good manufacturing practices, errors can occur, both human and in automated processes, thus causing the release of batches that should not have been approved. In summary, it is necessary for manufacturers to implement a robust and well structured quality system in order to avoid such deviations, and it is up to ANVISA to apply greater oversight in the post marketing of these products.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007835PMC
http://dx.doi.org/10.1186/s12913-023-09225-wDOI Listing

Publication Analysis

Top Keywords

good manufacturing
12
manufacturing practices
12
recall substandard
8
substandard medicines
8
medicines brazil
8
brazil period
8
simplified notification
8
recall
6
quality
6
medicines
5

Similar Publications

Background/objectives: Although extemporaneous formulations of anticancer drug products for personalized therapy are produced according to Good Hospital Pharmacy Manufacturing Practice, the lack of knowledge about drug stability under clinical conditions limits the second-time use of these highly costly medications in clinical practice. Therefore, the residual compounded drugs are considered waste and a cost item that negatively affects the healthcare system. In the context of the ever-increasing interest of the health system in applying practices in line with personalized medicine and spending review policies, this research aimed to demonstrate the feasibility of incorporating analytical techniques into daily routine practice.

View Article and Find Full Text PDF

Parenteral drug products manufactured under GMP conditions should be visually inspected for defects and particulate contamination by trained and qualified personnel. Although personnel qualification is required, no practical protocols or formal guidelines are available for the development of qualification test sets (QTSs) used for qualification procedures. The current practice is to either procure a standardized QTS from a commercial supplier or amass sufficient manufacturing rejects during visual inspection procedures to compile in-house QTSs.

View Article and Find Full Text PDF

In this research, poly(lactic acid) (PLA) nanocomposites with multi-walled carbon nanotubes (MWCNT) were produced by extrusion, injection, and compression molding, focusing on electromagnetic shielding. Various amounts of carbon nanotubes (MWCNTs) were tested in PLA matrix, specifically ranging from 1 to 4 parts per hundred resin (phr). The resulting nanocomposites were analyzed before and after undergoing annealing heat treatment.

View Article and Find Full Text PDF

Laser powder bed fusion (LPBF) is an additive manufacturing process that has gained interest for its material fabrication due to multiple advantages, such as the ability to print parts with small feature sizes, good mechanical properties, reduced material waste, etc. However, variations in the key process parameters in LPBF may result in the instantiation of porosity defects and variation in build rate. Particularly, volumetric energy density (VED) is a variable that encapsulates a number of those parameters and represents the amount of energy input from the laser source to the feedstock.

View Article and Find Full Text PDF

Cellular structures are increasingly utilized in modern engineering due to their exceptional mechanical and physical properties. In this study, the deformation and failure mechanisms of two energy-efficient lattice structures-hexagonal honeycomb and re-entrant honeycomb-were investigated. These structures were manufactured using additive stereolithography with light-curable Durable Resin V2.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!